Bausch Health Faces Setback as Phase 3 Trials Miss Targets

Bausch Health Companies Inc. stocks have been trading down by -9.95 percent amid FDA approval hurdles impacting investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BHC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Latest Developments in BHC’s Clinical Trials

Shares of Bausch Health dropped nearly 10% after announced that its Phase 3 RED-C clinical program failed to meet its primary endpoint.
The unsuccessful trials particularly impact Bausch Health’s efforts to gain ground in treating hepatic encephalopathy linked with liver cirrhosis.
Investor confidence is shaken as the company navigates both disappointing trial results and looming competition losses, including exclusivity of Xifaxan by 2027.
The market responded negatively with a 9.5% decline in Bausch Health’s stock, reflecting strong investor reaction to the trial outcomes.

Healthcare industry expert:

Analyst sentiment – negative

Bausch Health Companies Inc. (BHC) displays a mixed market position with strong gross margins at 85.1% and an impressive EBITDA margin of 33.4%, reflecting operational efficiency. However, the profitability is strained by a negative pretax profit margin of -3.3%, revealing challenges between revenue generation and cost management. The company’s Price-to-Earnings (P/E) ratio of 6.84, with an enterprise value indicating substantial debt, suggests undervaluation against market peers and ongoing financial leverage concerns particularly highlighted by a negative price-to-book value of -4.31. High long-term debt (204.63 billion) against weak equity conditions necessitates prudent capital management to ensure liquidity amid a modest current ratio of 1.3 and a comparatively low quick ratio of 0.3.

In technical analysis, Bausch Health’s stock trend reflects a weakening pattern, with the recent closing price at approximately $5.91, down from a weekly high of $6.79. The dominant trend is bearish, given the consistent lower lows and lower highs, alongside a recent sharp price decrease on January 23. This is underscored by a possible support level at $5.88. Trading volumes were substantial during the price drop, asserting the bearish sentiment of investors. A technical strategy suggests short positions should be considered if the price breaks below the $5.88 support level. Traders may set a target around $5.50 while monitoring for any bullish reversal signs.

Bausch Health is currently facing significant headwinds due to a failed Phase 3 RED-C trial and looming patent cliffs for its flagship drug Xifaxan by 2027. The unfavourable clinical outcomes have catalyzed a significant 9.5% decline in share price, emphasizing growing investor apprehension regarding future revenue streams and competitive positioning in pharmaceuticals. In contrast to sector benchmarks, BHC’s setback in critical drug development initiatives highlights strategic vulnerabilities. The inability to meet trial endpoints not only challenges near-term growth prospects but also hamstrings long-term innovation capabilities. Hence, the immediate outlook remains precarious with formidable resistance near previous highs around $6.79 and additional downside risks below key supports.

More Breaking News

Weekly Update Jan 19 – Jan 23, 2026: On Sunday, January 25, 2026 Bausch Health Companies Inc. stock [NYSE: BHC] is trending down by -9.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In the past couple of days, Bausch Health Company’s shares witnessed a notable dip, closing at $5.9166 on January 23, 2026, from an earlier high of $6.79 just days before. This decline coincides with the company’s public announcement regarding the Phase 3 RED-C trials. Additionally, the intra-day low was observed at $5.91, indicating potential volatility in trading patterns.

Financial metrics, such as the EBIT margin at 20.6% and a gross margin of 85.1%, reveal a company struggling to maintain profitability amid ongoing pressures. Meanwhile, the reported earnings show a mixed picture. Operating revenue was at $2.681B with net income reported at $179M for the last quarter, suggesting revenue generation is steady but not without its shortcomings. Furthermore, a price-to-sales ratio of 0.24 and a substantial enterprise value of $30.07B indicates market skepticism, often leading to stock price sensitivity. The absence of a noteworthy dividend yield reflects a more restrained approach in engaging investors, adding caution to the financial outlook. As operating cash flow remains robust at $405M, it underscores capable liquidity yet tempered by broader financial strain as development costs bite into potential gains.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!